Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction.
Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction.
复制标题
缺血性中风和心肌梗塞患者中MCP-1趋化因子的血清水平。
DOI：
10.1155/mi.2005.175
复制
发表时间：
2005-08-14
影响因子：
4.6
通讯作者：
Petrek M
中科院分区：
文献类型：
--
作者：
Arakelyan A;Petrkova J;Hermanova Z;Boyajyan A;Lukl J;Petrek M
趋化因子驱动的炎症细胞迁移与缺血性中风和心肌梗死等动脉粥样硬化相关疾病的发病机制有关。在这项研究中，一个候选趋化因子，单核细胞趋化蛋白（MCP）-1，在上述两种表现的动脉粥样硬化性炎症患者进行了研究。通过ELISA测定40名健康对照受试者（C）、40名缺血性中风（IS）患者和64名心肌梗死（MI）患者的血清中MCP-1水平。统计分析使用Mann-Whitney检验、Fisher精确检验和斯皮尔曼等级相关（P <0.05）。与对照受试者相比（C;中位数/四分位距：239/126 pg/mL），MCP-1血清水平在两个研究的患者队列中均升高（IS：384/370，P <0.001; MI：360/200，P <0.002）。MCP-1血清水平有很大的变化，尤其是在IS组。趋化因子水平与动脉粥样硬化危险因素（高血压、糖尿病、吸烟和饮酒）之间没有关系，MCP-1也与年龄或性别无关。MCP-1在动脉粥样硬化相关并发症患者循环中的升高涉及这种CC趋化因子配体（CCL）2在炎症过程中的作用，这有助于心肌梗死和缺血性卒中的发病机制。然而，需要进一步的研究，包括患者分层，以评估MCP-1是否可用于这些疾病患者的临床管理。
Chemokine-driven migration of inflammatory cells has been implicated in pathogenesis of atherosclerosis-associated conditions such as ischemic stroke and myocardial infarction. In this study, a candidate chemokine, monocyte chemoattractant protein (MCP)-1, was investigated in patients with both aforementioned manifestations of atheroslerotic inflammation. MCP-1 levels in serum were determined by ELISA in 40 healthy, control subjects (C), 40 patients with ischemic stroke (IS), and in 64 patients with myocardial infarction (MI). Statistical analysis utilised Mann-Whitney test, Fisher's exact test, and Spearman's rank correlation (P < .05). In comparison to control subjects (C; median/interquartile range: 239/126 pg/mL), MCP-1 serum levels were increased in both investigated patient cohorts (IS: 384/370, P < .001; MI: 360/200, P < .002). There was a substantial variability of MCP-1 serum levels, especially in the IS group. No relationship was observed between chemokine levels and atherosclerosis risk factors (hypertension, diabetes, smoking, and alcohol consumption), and MCP-1 was also not related to age or gender. Elevation of MCP-1 in circulation of patients with atherosclerosis-associated complications implicates this CC chemokine ligand (CCL)2 in inflammatory processes, which contribute to pathogenesis of myocardial infarction and ischemic stroke. Further investigations, including patient stratification, are however necessary to evaluate if MCP-1 can be utilised for clinical management of patients with these diseases.